Which trial do we need? How to treat Pseudomonas aeruginosa bacteraemia-proposal for an umbrella randomized controlled trial

Clin Microbiol Infect. 2023 Jul;29(7):829-831. doi: 10.1016/j.cmi.2023.03.029. Epub 2023 Mar 31.

Authors

Mayan Gilboa¹, David van Duin², Dafna Yahav³

Affiliations

¹ Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medicine, Tel-Aviv University, Israel.
² Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA.
³ Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel; Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: dafna.yahav@gmail.com.

PMID: 37004748
DOI: 10.1016/j.cmi.2023.03.029

No abstract available

Keywords: Antibiotic resistance; Ceftazidime; Piperacillin-tazobactam; Pseudomonas aeruginosa; β-Lactam.

Publication types

Randomized Controlled Trial

MeSH terms

Anti-Bacterial Agents / therapeutic use
Bacteremia* / drug therapy
Ceftazidime
Cephalosporins / therapeutic use
Humans
Microbial Sensitivity Tests
Penicillanic Acid
Pseudomonas Infections* / drug therapy
Pseudomonas Infections* / microbiology
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Ceftazidime
Cephalosporins
Penicillanic Acid